Vivani Medical Inc. (NASDAQ:VANI) expects to initiate the first clinical study for the NPM-115 program in Australia in the fourth quarter of 2024. The NPM-115 clinical program will evaluate the ...
Vivani’s GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing Vivani previously ...
On Thursday, Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the LIBERATE-1 trial in Australia. Vivani's lead program, NPM-115, ...
An FDA database analysis shows that reported adverse skin events after GLP-1 receptor agonist use are rare but can include rash and pruritus, highlighting a need for further research, according to a ...
NPM-115 (exenatide implant) generated significant weight loss comparable to injectable semaglutide (Ozempic®/Wegovy®) from a single administration with expected twice-yearly dosing Vivani discloses ...
Vivani expects to initiate the first clinical study supporting the NPM-115 program in the fourth quarter of 2024 The NPM-115 clinical program will consist of a series of studies designed to support ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. A large-scale clinical trial found ...
Assistant Controller of Patents (C.A. (COMM.IPD-PAT) 76/2022), the Delhi High Court upheld the refusal of a patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results